Recombinant Anti-CD39 Anticorps [rCD39/8682] (A314699)

Anti-CD39 Antibody [rCD39/8682]

Recombinant mouse monoclonal [rCD39/8682] antibody to CD39.

CD39, also known as ectonucleoside triphosphate diphosphohydrolase 1 (ENP1), is an integral membrane glycoprotein that acts as an extracellular nucleotide-hydrolyzing enzyme. CD39 inhibits ADP-induced platelet aggregation by hydrolyzing ADP to AMP, and ultimately generating Adenosine. Intracellular CD39 undergoes glycosylation at six N-glycosylation sites and translocates to the membrane in order to be an active enzyme. Alternative splicing gives rise to three CD39 isoforms, vascular, placenta I and placenta II. The placenta I isoform differs at the amino terminus whereas the placenta II isoform is missing amino acids 300-510 at the C-terminus. CD39 is expressed in vascular tissues including placenta, lung, skeletal muscle and kidney, as well as endothelium, smooth muscle, cardiac cells, lymphocytes, such as activated B cells, activated NK cells, macrophages, Dendridic cells and platelets. CD39 may be used as an anti-thrombic agent for pre-treating patients at risk for coronary artery occlusion and thrombic stroke.

IHC-P

Human tonsil or lymph node.

IHC: 1-2 µg/ml

Human

Recombinant full-length human CD39 protein.

Mouse

Monoclonal

rCD39/8682

kappa

Unconjugated

Protein A/G chromatography.

200 µg/ml

70-100 kDa

Liquid

Supplied in 10mM Phosphate Buffered Saline with 0.05% BSA and 0.05% Sodium Azide.

Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.

ATPDase, CD 39, CD39 antigen, DKFZp686D194, DKFZp686I093, Ecto apyrase, Ecto ATP diphosphohydrolase, Ecto-apyrase, Ecto-ATP diphosphohydrolase 1, Ecto-ATPase 1, Ecto-ATPDase 1, Ectonucleoside triphosphate diphosphohydrolase 1, ENTP1_HUMAN, ENTPD 1, ENTPD1, FLJ40921, FLJ40959, Lymphoid cell activation antigen, NTPDase 1, NTPDase1, SPG64